Dr. Luis Quintero, MD, MBA

Dr. Luis Quintero is an accomplished Executive Medical Director with over 25 years of leadership in global medical affairs, clinical development, and drug safety. He holds an MD from Metropolitan University and an MBA from Webster University, along with specialized training through an Oncology-Hematology Fellowship at NIH/NCI.

As a visionary leader, Dr. Quintero has been at the forefront of developing pioneering therapies, including Dabrafenib, Ipilimumab, Kymriah, Lapatinib, and Enzalutamide, driving significant advancements in immunotherapy and cell and gene therapies. His strategic oversight has enabled the global launch of over 10 oncology therapies, with a particular focus on expanding market access across Latin America.

Dr. Quintero is renowned for his ability to align clinical and commercial strategies with corporate objectives, ensuring regulatory success and market penetration. His leadership in engaging with global health authorities, including the FDA and EMA, has resulted in accelerated drug approvals and the optimization of patient safety strategies worldwide.

With a proven track record of delivering transformative results, Dr. Quintero has held pivotal roles at leading pharmaceutical companies, consistently driving innovation and growth. His expertise in expanding market access in Latin America and globally underscores his commitment to advancing healthcare on a global scale.